Literature DB >> 28034991

Impact of FLT3-ITD diversity on response to induction chemotherapy in patients with acute myeloid leukemia.

Mike Fischer1, Ulf Schnetzke1, Bärbel Spies-Weisshart1, Mario Walther2, Maximilian Fleischmann1, Inken Hilgendorf1, Andreas Hochhaus1, Sebastian Scholl3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 28034991      PMCID： PMC5395123          DOI： 10.3324/haematol.2016.157180

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Improved outcome after stem-cell transplantation in FLT3/ITD-positive AML.

Authors:  Martin Bornhäuser; Thomas Illmer; Markus Schaich; Silke Soucek; Gerhard Ehninger; Christian Thiede
Journal:  Blood       Date:  2007-03-01       Impact factor: 22.113

2.  Genomic landscapes and clonality of de novo AML.

Authors:  Christopher A Miller; Richard K Wilson; Timothy J Ley
Journal:  N Engl J Med       Date:  2013-10-10       Impact factor: 91.245

3.  Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.

Authors:  Christian Thiede; Christine Steudel; Brigitte Mohr; Markus Schaich; Ulrike Schäkel; Uwe Platzbecker; Martin Wermke; Martin Bornhäuser; Markus Ritter; Andreas Neubauer; Gerhard Ehninger; Thomas Illmer
Journal:  Blood       Date:  2002-06-15       Impact factor: 22.113

4.  The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials.

Authors:  P D Kottaridis; R E Gale; M E Frew; G Harrison; S E Langabeer; A A Belton; H Walker; K Wheatley; D T Bowen; A K Burnett; A H Goldstone; D C Linch
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

5.  No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials.

Authors:  Rosemary E Gale; Robert Hills; Panagiotis D Kottaridis; Sivatharsini Srirangan; Keith Wheatley; Alan K Burnett; David C Linch
Journal:  Blood       Date:  2005-08-02       Impact factor: 22.113

6.  A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML.

Authors:  Frank Breitenbuecher; Boyka Markova; Stefan Kasper; Birgit Carius; Torsten Stauder; Frank D Böhmer; Kristina Masson; Lars Rönnstrand; Christoph Huber; Thomas Kindler; Thomas Fischer
Journal:  Blood       Date:  2009-01-14       Impact factor: 22.113

7.  Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome.

Authors:  Sabine Kayser; Richard F Schlenk; Martina Correa Londono; Frank Breitenbuecher; Kerstin Wittke; Juan Du; Silja Groner; Daniela Späth; Jürgen Krauter; Arnold Ganser; Hartmut Döhner; Thomas Fischer; Konstanze Döhner
Journal:  Blood       Date:  2009-07-14       Impact factor: 22.113

8.  Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy.

Authors:  Marta Pratcorona; Salut Brunet; Josep Nomdedéu; Josep Maria Ribera; Mar Tormo; Rafael Duarte; Lourdes Escoda; Ramon Guàrdia; M Paz Queipo de Llano; Olga Salamero; Joan Bargay; Carmen Pedro; Josep Maria Martí; Montserrat Torrebadell; Marina Díaz-Beyá; Mireia Camós; Dolors Colomer; Montserrat Hoyos; Jorge Sierra; Jordi Esteve
Journal:  Blood       Date:  2013-02-01       Impact factor: 22.113

9.  Structural and numerical variation of FLT3/ITD in pediatric AML.

Authors:  Soheil Meshinchi; Derek L Stirewalt; Todd A Alonzo; Titus J Boggon; Robert B Gerbing; Jennifer L Rocnik; Beverly J Lange; D Gary Gilliland; Jerald P Radich
Journal:  Blood       Date:  2008-02-27       Impact factor: 22.113

10.  Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.

Authors:  Christoph Röllig; Hubert Serve; Andreas Hüttmann; Richard Noppeney; Carsten Müller-Tidow; Utz Krug; Claudia D Baldus; Christian H Brandts; Volker Kunzmann; Hermann Einsele; Alwin Krämer; Kerstin Schäfer-Eckart; Andreas Neubauer; Andreas Burchert; Aristoteles Giagounidis; Stefan W Krause; Andreas Mackensen; Walter Aulitzky; Regina Herbst; Mathias Hänel; Alexander Kiani; Norbert Frickhofen; Johannes Kullmer; Ulrich Kaiser; Hartmut Link; Thomas Geer; Albert Reichle; Christian Junghanß; Roland Repp; Frank Heits; Heinz Dürk; Jana Hase; Ina-Maria Klut; Thomas Illmer; Martin Bornhäuser; Markus Schaich; Stefani Parmentier; Martin Görner; Christian Thiede; Malte von Bonin; Johannes Schetelig; Michael Kramer; Wolfgang E Berdel; Gerhard Ehninger
Journal:  Lancet Oncol       Date:  2015-11-06       Impact factor: 41.316
View more
  10 in total

1.  Long Noncoding RNA SOCS2-AS Promotes Leukemogenesis in FLT3-ITD+ Acute Myeloid Leukemia Through miRNA-221.

Authors:  Rong Zhang; Cai-Hong Huo
Journal:  Onco Targets Ther       Date:  2020-04-05       Impact factor: 4.147

2.  Hematopoietic niche drives FLT3-ITD acute myeloid leukemia resistance to quizartinib via STAT5-and hypoxia-dependent upregulation of AXL.

Authors:  Pierre-Yves Dumas; Cécile Naudin; Séverine Martin-Lannerée; Brigitte Izac; Luana Casetti; Olivier Mansier; Benoît Rousseau; Alexandre Artus; Mélody Dufossée; Alban Giese; Pierre Dubus; Arnaud Pigneux; Vincent Praloran; Audrey Bidet; Arnaud Villacreces; Amélie Guitart; Noël Milpied; Olivier Kosmider; Isabelle Vigon; Vanessa Desplat; Isabelle Dusanter-Fourt; Jean-Max Pasquet
Journal:  Haematologica       Date:  2019-03-28       Impact factor: 9.941

3.  MEK inhibition enhances the response to tyrosine kinase inhibitors in acute myeloid leukemia.

Authors:  María Luz Morales; Alicia Arenas; Alejandra Ortiz-Ruiz; Alejandra Leivas; Inmaculada Rapado; Alba Rodríguez-García; Nerea Castro; Ivana Zagorac; Miguel Quintela-Fandino; Gonzalo Gómez-López; Miguel Gallardo; Rosa Ayala; María Linares; Joaquín Martínez-López
Journal:  Sci Rep       Date:  2019-12-09       Impact factor: 4.379

4.  Targeted Informatics for Optimal Detection, Characterization, and Quantification of FLT3 Internal Tandem Duplications Across Multiple Next-Generation Sequencing Platforms.

Authors:  Harrison K Tsai; Diane G Brackett; David Szeto; Ryan Frazier; Allison MacLeay; Phani Davineni; Danielle K Manning; Elizabeth Garcia; Neal I Lindeman; Long P Le; Jochen K Lennerz; Christopher J Gibson; R Coleman Lindsley; Annette S Kim; Valentina Nardi
Journal:  J Mol Diagn       Date:  2020-06-27       Impact factor: 5.568

5.  Exploration of the immune-related signature and immune infiltration analysis for breast ductal and lobular carcinoma.

Authors:  Bochuan Zhang; Qingfeng Wang; Chenghao Fu; Chunying Jiang; Shiliang Ma
Journal:  Ann Transl Med       Date:  2019-12

6.  Pharmacologic inhibition of STAT5 in acute myeloid leukemia.

Authors:  Bettina Wingelhofer; Barbara Maurer; Elizabeth C Heyes; Abbarna A Cumaraswamy; Angelika Berger-Becvar; Elvin D de Araujo; Anna Orlova; Patricia Freund; Frank Ruge; Jisung Park; Gary Tin; Siawash Ahmar; Charles-Hugues Lardeau; Irina Sadovnik; Dávid Bajusz; György Miklós Keserű; Florian Grebien; Stefan Kubicek; Peter Valent; Patrick T Gunning; Richard Moriggl
Journal:  Leukemia       Date:  2018-02-02       Impact factor: 11.528

7.  Clonal heterogeneity of FLT3-ITD detected by high-throughput amplicon sequencing correlates with adverse prognosis in acute myeloid leukemia.

Authors:  Katrin Schranz; Max Hubmann; Egor Harin; Sebastian Vosberg; Tobias Herold; Klaus H Metzeler; Maja Rothenberg-Thurley; Hanna Janke; Kathrin Bräundl; Bianka Ksienzyk; Aarif M N Batcha; Sebastian Schaaf; Stephanie Schneider; Stefan K Bohlander; Dennis Görlich; Wolfgang E Berdel; Bernhard J Wörmann; Jan Braess; Stefan Krebs; Wolfgang Hiddemann; Ulrich Mansmann; Karsten Spiekermann; Philipp A Greif
Journal:  Oncotarget       Date:  2018-07-10

Review 8.  Molecular Mechanisms of Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia: Ongoing Challenges and Future Treatments.

Authors:  Sebastian Scholl; Maximilian Fleischmann; Ulf Schnetzke; Florian H Heidel
Journal:  Cells       Date:  2020-11-17       Impact factor: 6.600

9.  Efficacy and Synergy of Small Molecule Inhibitors Targeting FLT3-ITD+ Acute Myeloid Leukemia.

Authors:  Javier Bregante; Anna Schönbichler; Daniel Pölöske; Lina Degenfeld-Schonburg; Garazi Monzó Contreras; Emir Hadzijusufovic; Elvin D de Araujo; Peter Valent; Richard Moriggl; Anna Orlova
Journal:  Cancers (Basel)       Date:  2021-12-08       Impact factor: 6.639

10.  FLT3-ITD mutations in acute myeloid leukaemia - molecular characteristics, distribution and numerical variation.

Authors:  Caroline Engen; Monica Hellesøy; Tim Grob; Adil Al Hinai; Atle Brendehaug; Line Wergeland; Siv Lise Bedringaas; Randi Hovland; Peter J M Valk; Bjørn T Gjertsen
Journal:  Mol Oncol       Date:  2021-05-02       Impact factor: 6.603
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.